[go: up one dir, main page]

MX2024000807A - Inhibidor de aak1 y uso de este. - Google Patents

Inhibidor de aak1 y uso de este.

Info

Publication number
MX2024000807A
MX2024000807A MX2024000807A MX2024000807A MX2024000807A MX 2024000807 A MX2024000807 A MX 2024000807A MX 2024000807 A MX2024000807 A MX 2024000807A MX 2024000807 A MX2024000807 A MX 2024000807A MX 2024000807 A MX2024000807 A MX 2024000807A
Authority
MX
Mexico
Prior art keywords
aak1 inhibitor
compound
aak1
inhibitor
stereoisomer
Prior art date
Application number
MX2024000807A
Other languages
English (en)
Inventor
Yan Yu
Pangke Yan
Xin Liu
Long Wang
Yao Li
Zongjun Shi
Chen Zhang
Pingming Tang
Fengkai Cheng
Wenjing Wang
Haoliang Zhang
Chenglong Du
Xiaozhuan Zhang
Original Assignee
Xizang Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xizang Haisco Pharmaceutical Co Ltd filed Critical Xizang Haisco Pharmaceutical Co Ltd
Publication of MX2024000807A publication Critical patent/MX2024000807A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de fórmula (I) y un estereoisómero, compuesto deuterado, solvato, profármaco, metabolito, sal farmacéuticamente aceptable o cocristal de este, o una composición farmacéutica que lo contiene, y el uso de este como un inhibidor de AAK1 en la preparación de un fármaco para tratar enfermedades relacionadas. (ver Fórmula).
MX2024000807A 2021-07-15 2022-07-14 Inhibidor de aak1 y uso de este. MX2024000807A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110801701 2021-07-15
CN202111105950 2021-09-22
CN202111324545 2021-11-10
CN202111465224 2021-12-03
PCT/CN2022/105793 WO2023284838A1 (zh) 2021-07-15 2022-07-14 Aak1抑制剂及其用途

Publications (1)

Publication Number Publication Date
MX2024000807A true MX2024000807A (es) 2024-02-06

Family

ID=84919074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000807A MX2024000807A (es) 2021-07-15 2022-07-14 Inhibidor de aak1 y uso de este.

Country Status (11)

Country Link
US (1) US20240343720A1 (es)
EP (1) EP4371980A4 (es)
JP (1) JP2024527618A (es)
KR (1) KR20240035814A (es)
CN (1) CN117715899A (es)
AU (1) AU2022310259A1 (es)
CA (1) CA3225894A1 (es)
MX (1) MX2024000807A (es)
TW (1) TW202317532A (es)
WO (1) WO2023284838A1 (es)
ZA (1) ZA202400988B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023167806A1 (en) * 2022-03-01 2023-09-07 Lexicon Pharmaceuticals, Inc. Methods and compounds useful in the sythesis of an aak1 inhibitor
WO2024099430A1 (zh) * 2022-11-10 2024-05-16 西藏海思科制药有限公司 一种含aak1抑制剂的药物组合物
WO2024153067A1 (zh) * 2023-01-16 2024-07-25 上海海雁医药科技有限公司 杂环取代的含氮杂环衍生物、其药物组合物及应用与制备方法
WO2024207945A1 (zh) * 2023-04-07 2024-10-10 艾立康药业股份有限公司 作为aak1抑制剂的氮杂环类化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619101A1 (en) * 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
PL2366699T3 (pl) 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-podstawiona pochodna izochinoliny i jej zastosowanie
WO2015006100A1 (en) * 2013-07-08 2015-01-15 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
CA2944466C (en) * 2014-04-02 2020-06-09 Bristol-Myers Squibb Company Biaryl kinase inhibitors
ES2765730T3 (es) 2015-10-01 2020-06-10 Bristol Myers Squibb Co Inhibidores de biaril cinasa
KR102707968B1 (ko) * 2015-10-01 2024-09-20 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제

Also Published As

Publication number Publication date
KR20240035814A (ko) 2024-03-18
CA3225894A1 (en) 2023-01-19
EP4371980A1 (en) 2024-05-22
TW202317532A (zh) 2023-05-01
AU2022310259A1 (en) 2024-02-29
EP4371980A4 (en) 2024-12-11
CN117715899A (zh) 2024-03-15
ZA202400988B (en) 2024-10-30
JP2024527618A (ja) 2024-07-25
WO2023284838A1 (zh) 2023-01-19
US20240343720A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
ZA202400988B (en) Aak1 inhibitor and use thereof
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
JOP20190229B1 (ar) مركبات تثبط بروتين mcl-1
PH12022551454A1 (en) Pyrazolyl derivatives useful as anti-cancer agents
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
ZA202306652B (en) Five-membered ring derivative and medical use thereof
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
MX2019006843A (es) Inhibidor de cdk4/6.
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
PH12023552774A1 (en) Nek7 inhibitors
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12022550531A1 (en) Irak inhibitor and preparation method therefor and use thereof
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).